Additional evidence from trials such as ODYSSEY DM-INSULIN and ODYSSEY DM-DYSLIPIDEMIA highlighted the efficacy of PCSK9 inhibitors in individuals with hypercholesterolemia and diabetes [131,132]. Here, PCSK9 is linked to familial hypercholesterolemia.